PL3302565T3 - Stałe postacie dawkowane palbocyklibu - Google Patents

Stałe postacie dawkowane palbocyklibu

Info

Publication number
PL3302565T3
PL3302565T3 PL16726192T PL16726192T PL3302565T3 PL 3302565 T3 PL3302565 T3 PL 3302565T3 PL 16726192 T PL16726192 T PL 16726192T PL 16726192 T PL16726192 T PL 16726192T PL 3302565 T3 PL3302565 T3 PL 3302565T3
Authority
PL
Poland
Prior art keywords
palbociclib
dosage forms
solid dosage
solid
forms
Prior art date
Application number
PL16726192T
Other languages
English (en)
Inventor
Fady Makram Louiz IBRAHIM
Matthew Patrick MULLARNEY
Ravi Mysore Shanker
Barbara Rodriguez SPONG
Jian Wang
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56092955&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3302565(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of PL3302565T3 publication Critical patent/PL3302565T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PL16726192T 2015-06-04 2016-05-24 Stałe postacie dawkowane palbocyklibu PL3302565T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562171177P 2015-06-04 2015-06-04
US201662332973P 2016-05-06 2016-05-06
EP16726192.4A EP3302565B1 (en) 2015-06-04 2016-05-24 Solid dosage forms of palbociclib
PCT/IB2016/053040 WO2016193860A1 (en) 2015-06-04 2016-05-24 Solid dosage forms of palbociclib

Publications (1)

Publication Number Publication Date
PL3302565T3 true PL3302565T3 (pl) 2020-06-01

Family

ID=56092955

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16726192T PL3302565T3 (pl) 2015-06-04 2016-05-24 Stałe postacie dawkowane palbocyklibu

Country Status (31)

Country Link
US (2) US11065250B2 (pl)
EP (2) EP3636283A1 (pl)
JP (3) JP2017002034A (pl)
KR (2) KR102369405B1 (pl)
CN (2) CN113616606A (pl)
AU (2) AU2016272881C1 (pl)
BR (1) BR112017025398A2 (pl)
CA (1) CA2931892A1 (pl)
CL (1) CL2017003089A1 (pl)
CO (1) CO2017012362A2 (pl)
CR (1) CR20170540A (pl)
CY (1) CY1122454T1 (pl)
DK (1) DK3302565T3 (pl)
DO (1) DOP2017000280A (pl)
ES (1) ES2764459T3 (pl)
HK (1) HK1250570A1 (pl)
HR (1) HRP20192065T1 (pl)
HU (1) HUE047477T2 (pl)
IL (2) IL255632A (pl)
LT (1) LT3302565T (pl)
MX (2) MX2017015579A (pl)
PE (1) PE20180395A1 (pl)
PL (1) PL3302565T3 (pl)
PT (1) PT3302565T (pl)
RS (1) RS59672B1 (pl)
RU (1) RU2686840C1 (pl)
SA (1) SA517390473B1 (pl)
SI (1) SI3302565T1 (pl)
TW (2) TWI635863B (pl)
WO (1) WO2016193860A1 (pl)
ZA (1) ZA201707780B (pl)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3628319T3 (pl) 2008-10-02 2024-04-29 Salix Pharmaceuticals, Ltd. Leczenie encefalopatii wątrobowej za pomocą ryfaksyminy
CN105616418A (zh) * 2014-11-07 2016-06-01 江苏豪森药业集团有限公司 含有细胞周期蛋白抑制剂的药物制剂及其制备方法
WO2017115315A1 (en) * 2015-12-30 2017-07-06 Dr. Reddy's Laboratories Limited Solid forms of palbociclib
US10449195B2 (en) 2016-03-29 2019-10-22 Shenzhen Pharmacin Co., Ltd. Pharmaceutical formulation of palbociclib and a preparation method thereof
CN109078006B (zh) * 2016-03-29 2021-04-20 深圳市药欣生物科技有限公司 一种帕布昔利布的药物制剂及其制备方法
CN108210454A (zh) * 2016-12-14 2018-06-29 深圳市华力康生物医药有限公司 一种帕布昔利布的口服乳剂及其制备方法
US20190381025A1 (en) * 2017-01-20 2019-12-19 Constellation Pharmaceuticals, Inc. Solid dispersions of (r)-n-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1h-indole-3-carboxamide
AU2018231044B2 (en) * 2017-03-08 2023-04-06 Cinrx Pharma, Llc Pharmaceutical formulations of phloroglucinol and trimethylphloroglucinol
US20200054560A1 (en) * 2017-04-21 2020-02-20 Alnova Pharmaceuticals, Ltd. Palbociclib compositions and methods thereof
KR20200013714A (ko) * 2017-05-31 2020-02-07 베링거 인겔하임 인터내셔날 게엠베하 (e)-4-(2-(아미노메틸)-3-플루오로알릴옥시)-n-3급-부틸벤즈아미드를 포함하는 약제학적 조성물 및 약제학적 투여 형태, 이들의 제조 방법, 이의 치료 방법 및 용도
CN106970177B (zh) * 2017-06-06 2018-05-15 北京元延医药科技股份有限公司 帕博西尼中间体及其杂质的分析检测方法
WO2019013310A1 (en) 2017-07-10 2019-01-17 Takeda Pharmaceutical Company Limited PREPARATION COMPRISING VONOPRAZAN
EP3658119A1 (en) * 2017-07-28 2020-06-03 Synthon B.V. Pharmaceutical composition comprising palbociclib
WO2019056163A1 (zh) * 2017-09-19 2019-03-28 浙江华海药业股份有限公司 N-甲酰基帕博西尼及其制备方法和用途以及帕博西尼制剂及其质量控制方法
WO2019084462A1 (en) * 2017-10-27 2019-05-02 Plexxikon Inc. FORMULATION OF A COMPOUND MODULATING KINASES
CN108014343A (zh) * 2017-12-21 2018-05-11 孟斯琴 一种治疗乳腺癌的药物组合物及其制备方法
CN108066303A (zh) * 2017-12-31 2018-05-25 湖南博隽生物医药有限公司 一种抗癌药物组合物及其制备方法
CA3092003A1 (en) 2018-02-27 2019-09-06 Pfizer Inc. Combination of a cyclin dependent kinase inhibitor and a bet-bromodomain inhibitor
US11911383B2 (en) 2018-05-14 2024-02-27 Pfizer Inc. Oral solution formulation
AU2019269815A1 (en) * 2018-05-15 2020-10-22 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Pharmaceutical composition comprising small molecule EGFR inhibitor and preparation method therefor
CN108653222A (zh) * 2018-07-03 2018-10-16 威海贯标信息科技有限公司 一种帕博西尼片剂组合物
CN109575021B (zh) * 2019-01-22 2020-09-18 北京海美桐医药科技有限公司 一种哌柏西利的制备方法
US20220125777A1 (en) 2019-02-01 2022-04-28 Pfizer Inc. Combination of a cdk inhibitor and a pim inhibitor
CR20220342A (es) 2019-12-16 2023-01-23 Lunella Biotech Inc Agentes terapéuticos selectivos contra el cáncer inhibidores cdk4/6
JP2023507140A (ja) 2019-12-16 2023-02-21 ルネラ・バイオテック・インコーポレーテッド 選択的ｃｄｋ４／６阻害剤のがん治療薬
EP4176902A1 (en) * 2020-07-02 2023-05-10 Artham Therapeutics Inc. Oral pharmaceutical composition and method for producing same
CA3189632A1 (en) 2020-07-20 2022-01-27 Pfizer Inc. Combination therapy
CN114246872B (zh) * 2020-09-24 2024-02-06 南京济群医药科技股份有限公司 一种改善羟乙磺酸哌柏西利流动性的工艺方法及组合物
CN114306245A (zh) 2020-09-29 2022-04-12 深圳市药欣生物科技有限公司 无定形固体分散体的药物组合物及其制备方法
WO2022091001A1 (en) 2020-10-29 2022-05-05 Pfizer Ireland Pharmaceuticals Process for preparation of palbociclib
WO2022123419A1 (en) 2020-12-08 2022-06-16 Pfizer Inc. Treatment of luminal subtypes of hr-positive, her2-negative early breast cancer with palbociclib
WO2022162122A1 (en) 2021-01-29 2022-08-04 Biotx.Ai Gmbh Genetically verified netosis inhibitor for use in the treatment of a sars-cov2 infection
EP4302832A1 (en) 2022-07-07 2024-01-10 Lotus Pharmaceutical Co., Ltd. Palbociclib formulation containing glucono delta lactone
EP4302755A1 (en) 2022-07-07 2024-01-10 Lotus Pharmaceutical Co., Ltd. Palbociclib formulation containing an amino acid

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
TW477787B (en) 1996-08-27 2002-03-01 Pfizer Pyrido six-membered nitrogen-containing cyclic ring derivatives having corticotropin releasing factor antagonist activity and pharmaceutical composition containing same
CN1237177A (zh) 1996-11-27 1999-12-01 辉瑞大药厂 稠合的二环嘧啶衍生物
SI1470124T1 (sl) 2002-01-22 2006-04-30 Warner Lambert Co 2-(piridin-2-ilamino)-pirido(2,3-d)pirimidin-7-oni
US20030181488A1 (en) 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
EP1648889B1 (en) * 2003-07-11 2008-10-29 Warner-Lambert Company LLC Isethionate salt of a selective cdk4 inhibitor
GB0317663D0 (en) * 2003-07-29 2003-09-03 Astrazeneca Ab Pharmaceutical composition
CA2619035A1 (en) 2005-08-22 2007-03-01 Novartis Ag Pharmaceutical compositions
GB0517204D0 (en) * 2005-08-22 2005-09-28 Novartis Ag Organic compounds
ES2533563T5 (es) 2006-01-27 2018-07-24 Adare Pharmaceuticals, Inc. Sistemas de suministro de fármacos que comprenden fármacos débilmente básicos y ácidos orgánicos
BRPI0716880A2 (pt) 2006-09-08 2013-10-15 Pfizer Prod Inc Síntese de 2-(piridin-2-ilamino)-pirido[2,3-d]pirimidin-7-onas
SI2074122T1 (sl) 2006-09-15 2011-10-28 Pfizer Prod Inc Pirido (2,3-d)pirimidinonske spojine in njihova uporaba kot zaviralci PI3
WO2011039527A1 (en) * 2009-09-30 2011-04-07 Merck Sharp & Dohme Ltd Formulations for c-met kinase inhibitors
CN103002880B (zh) * 2010-06-09 2015-01-28 Abbvie公司 含有激酶抑制剂的固态分散体
CA2856406C (en) 2011-11-23 2020-06-23 Novartis Ag Pharmaceutical formulations
EP2793864A1 (en) 2011-12-22 2014-10-29 Boehringer Ingelheim International GmbH Immediate release multi unit pellet system
SI2958916T1 (sl) * 2013-02-21 2018-11-30 Pfizer Inc. Trdne oblike selektivnih zaviralcev CDK4/6
DK3033086T3 (da) * 2013-08-14 2022-01-03 Novartis Ag Kombinationsterapi til behandling af cancer
US20150140036A1 (en) * 2013-11-13 2015-05-21 Novartis Institutes For Biomedical Research, Inc. Low, immune enhancing, dose mtor inhibitors and uses thereof
WO2016156070A1 (en) 2015-04-02 2016-10-06 Sandoz Ag Modified particles of palbociclib
CN109078006B (zh) 2016-03-29 2021-04-20 深圳市药欣生物科技有限公司 一种帕布昔利布的药物制剂及其制备方法
US10449195B2 (en) 2016-03-29 2019-10-22 Shenzhen Pharmacin Co., Ltd. Pharmaceutical formulation of palbociclib and a preparation method thereof

Also Published As

Publication number Publication date
EP3302565B1 (en) 2019-11-06
TWI635863B (zh) 2018-09-21
TWI763881B (zh) 2022-05-11
SA517390473B1 (ar) 2022-12-11
DOP2017000280A (es) 2018-01-15
WO2016193860A1 (en) 2016-12-08
TW201906611A (zh) 2019-02-16
CO2017012362A2 (es) 2018-03-28
KR102068423B1 (ko) 2020-01-20
EP3636283A1 (en) 2020-04-15
AU2019204689B2 (en) 2020-12-03
IL287437A (en) 2021-12-01
CR20170540A (es) 2018-02-02
PT3302565T (pt) 2020-01-14
AU2016272881C1 (en) 2019-10-03
SI3302565T1 (sl) 2020-02-28
ZA201707780B (en) 2020-05-27
HUE047477T2 (hu) 2020-04-28
CN113616606A (zh) 2021-11-09
US11065250B2 (en) 2021-07-20
JP2017002034A (ja) 2017-01-05
AU2016272881B2 (en) 2019-04-11
KR20200006633A (ko) 2020-01-20
ES2764459T3 (es) 2020-06-03
KR102369405B1 (ko) 2022-03-02
TW201711687A (zh) 2017-04-01
AU2016272881A1 (en) 2017-12-07
MX2017015579A (es) 2018-03-27
KR20180015232A (ko) 2018-02-12
IL255632A (en) 2018-01-31
PE20180395A1 (es) 2018-02-28
BR112017025398A2 (pt) 2018-08-07
JP2021167343A (ja) 2021-10-21
RU2686840C1 (ru) 2019-05-06
LT3302565T (lt) 2019-12-27
US20210315900A1 (en) 2021-10-14
DK3302565T3 (da) 2020-01-02
JP2023112149A (ja) 2023-08-10
MX2020003825A (es) 2020-08-06
CN107666914A (zh) 2018-02-06
AU2019204689A1 (en) 2019-07-18
HRP20192065T1 (hr) 2020-02-21
US20180207100A1 (en) 2018-07-26
EP3302565A1 (en) 2018-04-11
HK1250570A1 (zh) 2018-12-28
RS59672B1 (sr) 2020-01-31
NZ737391A (en) 2023-11-24
CA2931892A1 (en) 2016-12-04
CY1122454T1 (el) 2021-01-27
CL2017003089A1 (es) 2018-05-11

Similar Documents

Publication Publication Date Title
IL287437A (en) Flavociclib solid dosage forms
IL249946A0 (en) High Dose Strength Rocaprib Tablets
HK1258062A1 (zh) 給予惡拉戈利的方法
SG11201706729SA (en) Derivatives of sobetirome
IL257026A (en) Solid state forms of eluxadoline
SI3845221T1 (sl) Trdne oblike sofosbuvirja
IL285882A (en) Medicinal uses for l–4–chlorokynurenine
ZA201706282B (en) Solid forms of menaquinols
IL246979A0 (en) Crystalline forms of sofosbuvir
HK1223624A1 (zh) 替諾福韋的固體形式
IL249130A0 (en) Preparation of piperidine-4-carbthioamide
GB201607548D0 (en) Solid dosage form
HRP20181406T1 (hr) Farmaceutski dozni oblici
IL249332A0 (en) Crystalline forms of sofosbuvir
GB201512635D0 (en) Uses of therapeutic compounds
GB201502041D0 (en) Solid dosage form production
TWM490331U (en) Improved structure of mask